EUVIMEDOpdag EUVIMED
LeserbriefKommentar

Reply to: Comments on “Association of calcium and vitamin D supplementation with cancer incidence and cause‐specific mortality in Black women: Extended follow‐up of the Women's Health Initiative calcium‐vitamin D trial”

Ikuko Kato iD, Joseph C Larson

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34501 ↗

At a glance

Leserbrief in International Journal of Cancer, 2023. Written by Ikuko Kato and 1 co-authors. Institution: Department of Oncology, Wayne State University, Detroit, Michigan, USA. Major MEDLINE topics: Calcium, Neoplasms. 5 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Dear editor, Dr Grant raises important issues surrounding the chemopreventive potential of vitamin D; however, we disagree with several of his statements. Notably, he questioned the use of “Intent-To-Treat” (ITT) analysis, instead emphasizing secondary analyses restricted to subcohorts that met certain a posteriori selected conditions. However, ITT analysis for the primary outcome is regarded as the gold standard for randomized clinical trials. If intervention benefits only a fraction of the cohort, then the subgroup findings should be considered hypothesisgenerating and the intervention should be tested for efficacy in a new trial targeting that population expectedly more responsive or the intervention should be reformulated to improve adherence or bioavailability. Since vitamin D catabolic enzymes, such as CYP24A, are induced by 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D, Dr Grant's estimate of the effect of 400 IU supplementation on circulating 25-hydroxyvitamin D levels, 3 ng/mL, which was directly proportional to that of 2000 IU, does not seem well rationalized. In fact, in the second paragraph of the Discussion, we described actual plasma 25-hydroxyvitamin D levels measured in subsamples of this cohort, which showed 47% increase (equivalent to 6.5 ng/mL) over 2-year supplementation. 25-Hydroxyvitamin D levels rise more markedly with supplementation when baseline 25-hydroxyvitamin D levels are low, just as in the case of our study participants consisting of black individuals. Furthermore, we pointed out in the same paragraph the lack of benefits from vitamin D supplementation in other trials testing much higher doses. Accordingly, we interpreted that the low dose was not likely to be the primary cause of the null results. While we do appreciate the value of observational epidemiological studies, it is imperative to acknowledge that compelling findings from observational epidemiological studies have often been refuted by subsequent RCTs, as in the case of beta-carotene and combined postmenopausal hormonal therapy. In addition, we understand that Mendelian randomization studies are a powerful tool to infer causal associations, but they cannot be used to replace RCT. As also discussed in our publication, the overall null effect observed in this trial does not necessarily rule out potential beneficial effects on specific conditions, such as colorectal cancer or respiratory diseases. Given minimal risk reported from taking low-to-moderate doses of vitamin D, we do not advocate stopping vitamin D for individuals who are already taking the supplements. However, we expect that vitamin D supplementation has no measurable impact on incidence of most chronic diseases and thus other new medical, behavioral or social interventional approaches should be considered to reduce overall health disparity in black individuals. Finally, we appreciate his comments on an historical view of vitamin D and health in black individuals and hope to find another opportunity to address the issue elsewhere.

Subjects

MeSH terms (MEDLINE)

CalciumNeoplasmsFemaleHumansFollow-Up StudiesCause of DeathIncidenceVitamin DCalcium, DietaryWomen's HealthDietary Supplements

Substances

CalciumVitamin DCalcium, Dietary

Authors and institutions

  • Department of Oncology, Wayne State University, Detroit, Michigan, USA.
  • Department of Pathology, Wayne State University, Detroit, Michigan, USA.
  • Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

ORCID profiles: Ikuko Kato

Cite

APA

Kato, I., & Larson, J. C. (2023). Reply to: Comments on “Association of calcium and vitamin D supplementation with cancer incidence and cause‐specific mortality in Black women: Extended follow‐up of the Women's Health Initiative calcium‐vitamin D trial”. International Journal of Cancer. https://doi.org/10.1002/ijc.34501

Vancouver

Kato I, Larson JC. Reply to: Comments on “Association of calcium and vitamin D supplementation with cancer incidence and cause‐specific mortality in Black women: Extended follow‐up of the Women's Health Initiative calcium‐vitamin D trial”. International Journal of Cancer. 2023. doi:10.1002/ijc.34501

BibTeX
@article{Kato2023,
  author = {Kato, Ikuko and Larson, Joseph C},
  title = {Reply to: Comments on “Association of calcium and vitamin D supplementation with cancer incidence and cause‐specific mortality in Black women: Extended follow‐up of the Women's Health Initiative calcium‐vitamin D trial”},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34501}
}
Start for free →